X @Bloomberg

LEO Pharma agreed to acquire the global rights for skin disease drug Spevigo from Boehringer, as the Danish dermatology specialist strengthens its portfolio ahead of a planned IPO in 2026 https://t.co/hCCBv5pCxI ...